Effects of erythropoiesis-stimulating agents on survival and other outcomes in patients with lymphoproliferative malignancies: A study-level meta-analysis

Leukemia and Lymphoma

Volumn 53, Issue 11, 2012, Pages 2151-2158

  Hedenus, Michael ^a   Österborg, Anders ^b   Tomita, Dianne ^c   Bohac, Chet ^c   Coiffier, Bertrand ^d  

^a SUNDSVALL HOSPITAL   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c AMGEN INC   (United States)

^d UNIVERSITÉ LYON 1   (France)

Author keywords

Erythropoiesis stimulating agent; lymphoproliferative malignancies; meta analysis

Indexed keywords

ANTIANEMIC AGENT; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; DISEASE COURSE; DRUG SAFETY; ERYTHROCYTE TRANSFUSION; HEART FAILURE; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; LUNG EMBOLISM; LYMPHOPROLIFERATIVE DISEASE; LYMPHOPROLIFERATIVE MALIGNANCY; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; THROMBOEMBOLISM;

BLOOD TRANSFUSION; DISEASE PROGRESSION; HEMATINICS; HUMANS; LYMPHOPROLIFERATIVE DISORDERS; THROMBOEMBOLISM;

EID: 84867172326     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.684347     Document Type: Article

References (35)

1. ® (darbepoetin alfa) package insert. T ousand Oaks, CA: Amgen Inc.; 2011.
2. ® (darbepoetin alfa) package insert. Breda, The Netherlands: Amgen Inc.; 2011.
3. European public assessment reports for authorised medicinal products for human use [Internet]. Available from: http://www.emea. europa.eu/htms/human/ epar/a.htm
4. ® (epoetin alfa) prescribing information. Horsham, PA: Janssen Products LP; 2011.
5. ® (epoetin beta) summary of product characteristics. Welwyn Garden City, UK: Roche Products Limited 2010.
6. ® (epoetin beta) product information. Dee Why, Australia: Roche Product Pty Limited 2011.
7. Ö sterborg A, Boogaerts MA, Cimino R, et al. Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma-a randomized multicenter study. The European Study Group of Erythropoietin (Epoetin Beta) Treatment in Multiple Myeloma and Non-Hodgkin's Lymphoma. Blood 1996;87:2675-2682. (Pubitemid 26102216)
8. Littlewood TJ, Bajetta E, Nortier JW, et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001;19:2865-2874. (Pubitemid 32538196)
9. Vansteenkiste J, Pirker R, Massuti B, et al. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 2002;94:1211-1220. (Pubitemid 34993871)
10. Hedenus M, Adriansson M, San Miguel J, et al. Effcacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Br J Haematol 2003;122:394-403. (Pubitemid 36951623)
11. Barbara JA. The rationale for pathogen-inactivation treatment of blood components. Int J Hematol 2004;80:311-316. (Pubitemid 39564630)
12. Eder A F, Chambers LA. Noninfectious complications of blood transfusion. Arch Pathol Lab Med 2007;131:708-718. (Pubitemid 46726132)
13. Looney MR, Gropper MA, Matthay MA. Transfusion-related acute lung injury: a review. Chest 2004;126:249-258. (Pubitemid 38943143)
14. EMEA. electronic Medicines Compendium (eMC) [Internet]. Available from: http://emc.medicines.org.uk
15. Bennett CL, Silver SM, Djulbegovic B, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008;299:914-924. (Pubitemid 351397066)
16. Bohlius J, Wilson J, Seidenfeld J, et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 2006;98:708-714. (Pubitemid 43821788)
17. Hedenus M, Vansteenkiste J, Kotasek D, et al. Darbepoetin alfa for the treatment of chemotherapy-induced anemia: disease progression and survival analysis from four randomized, double-blind, placebo-controlled trials. J Clin Oncol 2005;23:6941-6948.
18. Amgen Inc. in collaboration with Johnson & Johnson Pharmaceutical Research and Development, L.L.C. Background information for the Oncologic Drugs Advisory Comittee (ODAC) meeting, 13 March 2008 [Internet]. http://www.fda. gov/ohrms/dockets/ac/08/brief ng/2008-4345b2-00-FDA-index.htm
19. Katodritou E, Verrou E, Hadjiaggelidou C, et al. Erythropoiesis- stimulating agents are associated with reduced survival in patients with multiple myeloma. Am J Hematol 2008;83:697-701.
20. Ludwig H, Anderson K, Dammacco F, et al. ESAs not the culprit: more studies required. Am J Hematol 2008;83:880; author reply 880-881.
21. Bohlius J, Schmidlin K, Brillant C, et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 2009;373:1532-1542.
22. Glaspy J, Crawford J, Vansteenkiste J, et al. Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Br J Cancer 2010;102:301-315.
23. Tonelli M, Hemmelgarn B, Reiman T, et al. Benef ts and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis. CMAJ 2009;180:E62-E71.
24. Cazzola M, Messinger D, Battistel V, et al. Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: dose f nding and identif cation of predictors of response. Blood 1995;86:4446-4453.
25. Dammacco F, Castoldi G, Rodjer S. Effcacy of epoetin alfa in the treatment of anaemia of multiple myeloma. Br J Haematol 2001;113:172-179. (Pubitemid 32423318)
26. Cabanillas M, Kantarjian H, T omas D, et al. Epoetin alpha decreases the number of erythrocyte transfusions in patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, and Burkitt leukemia/lymphoma. Cancer 2012;118:848-855.
27. Österborg A, Brandberg Y, Hedenus M. Impact of epoetin-beta on survival of patients with lymphoproliferative malignancies: long-term follow up of a large randomized study. Br J Haematol 2005;129:206-209. (Pubitemid 40562441)
28. Pangalis GA, Poziopoulos C, Angelopoulou MK, et al. Effective treatment of disease-related anaemia in B-chronic lymphocytic leukaemia patients with recombinant human erythropoietin. Br J Haematol 1995;89:627-629.
29. Engert A, Josting A, Haverkamp H, et al. Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial. J Clin Oncol 2010;28:2239-2245.
30. Delarue R, Haioun C, Coifier B, et al. Survival ef ect of darbepoetin alfa in patients with diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: the LNH03-6B study. J Clin Oncol 2011;29(Suppl.): Abstract 9048.
31. Hedenus M, Hansen S, Taylor K, et al. Randomized, dose-f nding study of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies. Br J Haematol 2002;119:79-86. (Pubitemid 35176501)
32. Rose E, Rai K, Revicki D, et al. Clinical and health status assessments in anemic chronic lymphocytic leukemia (CLL) patients treated with epoetin alfa (EPO). Blood 1994;84(Suppl. 1): Abstract 2091.
33. Cazzola M, Beguin Y, Kloczko J, et al. Once-weekly epoetin beta is highly ef ective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production. Br J Haematol 2003;122:386-393. (Pubitemid 36951622)
34. Österborg A, Brandberg Y, Molostova V, et al. Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies. J Clin Oncol 2002;20:2486-2494. (Pubitemid 34525734)
35. Aapro M, Coifier B, Dunst J, et al. Effect of treatment with epoetin beta on short-term tumour progression and survival in anaemic patients with cancer: a meta-analysis. Br J Cancer 2006;95:1467-1473. (Pubitemid 44867480)